IL6 and colorectal carcinoma: Studies on mice with colitis-associated cancer have found that treatment with anti-IL-6 receptor antibodies reduces the incidence of cancer, suggesting that IL-6 may be a therapeutic target for colorectal cancer (CRC) [202].